Références bibliographiques

Bilan d'extension et prise en charge

Stahl M, Kataja VV, Oliveira J; ESMO Guidelines Task Force.
ESMO Minimal Clinical Recommendations for diagnosis, treatment and follow-up of esophageal cancer.
Ann Oncol 2005;16 Suppl 1:i26-7.

Lightdale CJ, Kulkarni KG.
Role of endoscopic ultrasonography in the staging and follow-up of esophageal cancer.
J Clin Oncol 2005;23:4483-9.

Place de la chirurgie

Hofstetter W, Swisher SG, Correa AM, Hess K, Putnam JB, Ajani JA et al.
Treatment outcomes of resected esophageal cancer.
Ann Surg 2002;236:376-84

Akiyama H, Tsurumaru M, Udagawa H, Kajiyama Y.
Radical lymph node dissection for cancer of the thoracic esophagus.
Ann Surg 1994 ;220 :364-72

Hulscher JB, van Sandick JW, de Boer AG, Wijnhoven BP, Tijssen JG, Fockens P et al. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus.
N Engl J Med 2002;347:1662-9

Place de la chimiothérapie préopératoire

Medical Research Council Oesophageal Cancer Working Group.
Surgical resection with or without preoperative chemotherapy in oesophageal cancer : a randomised controlled trial.
Lancet 2002 ;359:1727-33

Allum W. H., P. J. Fogarty, S. P. Stenning, R. E. Langley, NCRI Upper GI Cancer Clinical Studies Group
Long term results of the MRC OEO2 randomized trial of surgery with or without preoperative chemotherapy in resectable esophageal cancer
ASCO Gastrointestinal Cancers Symposium 2008 abstract  9

V. Boige, J. Pignon, B. Saint-Aubert, P. Lasser, T. Conroy, O. Bouché, et al.
Final results of a randomized trial comparing preoperative 5-fluorouracil (F)/cisplatin (P) to surgery alone in adenocarcinoma of stomach and lower esophagus (ASLE): FNLCC ACCORD07-FFCD 9703 trial.
J Clin Oncol, 2007 ; 25, 18S (Suppl. Part I): résumé 4510

P. G. Thirion, S. Michiels, A. Le Maître, J. Tierney, on behalf of the MetaAnalysis of
Chemotherapy in Esophagus Cancer Collaborative Group.
Individual patient data-based meta-analysis assessing pre-operative chemotherapy in resectable oesophageal carcinoma.
J Clin Oncol, 2007 ; 25, 18S (Suppl. Part I): résumé 4512

Place de la radiochimiothérapie préopératoire

Gebski V, Burmeister B, Smithers BM, Foo K, Zalcberg J, Simes J.
Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis.
Lancet Oncol 2007;8:226-34.

Place et modalités de la chimioradiothérapie

Minsky BD, Pajak TF, Ginsberg RJ, Pisansky TM, Martenson J, Komaki R, et al.
INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy.
J Clin Oncol 2002;20:1167-74.

Wong RK, Malthaner RA, Zuraw L, Rumble RB
Combined modality radiotherapy and chemotherapy in nonsurgical management of localized carcinoma of the esophagus: a practice guideline.
Int J Radiat Oncol Biol Phys 2003;55:930-42.

Thomas CR, Berkey BA, Minsky BD, Gaspar LE, Herskovic A, Rich TA, et al.
Recursive partitioning analysis of pretreatment variables of 416 patients with locoregional esophageal cancer treated with definitive concomitant chemoradiotherapy on Intergroup and Radiation Therapy Oncology Group trials.
Int J Radiat Oncol Biol Phys2004;58:1405-10.